Advertisement

A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)

Published:October 15, 2020DOI:https://doi.org/10.1016/j.cllc.2020.09.023

      Abstract

      Background

      Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated advanced non–small-cell lung cancer (NSCLC). However, disease progression occurs within 19 months of treatment. In the NEJ009 study, gefitinib plus carboplatin plus pemetrexed demonstrated significantly better progression-free and overall survival compared with gefitinib monotherapy. Furthermore, the Lung Oncology Group in Kyushu and North East Japan Study Group, major clinical trial groups in Japan, conducted a randomized phase II study to evaluate the efficacy and safety of second-line osimertinib plus carboplatin plus pemetrexed versus osimertinib monotherapy for patients with disease progression during first-line EGFR tyrosine kinase inhibitor therapy and the EGFR T790M resistance mutation (TAKUMI trial; trial registration no., jRCTs071180062). In the first treatment course for the initial 24 patients, no safety issues were reported in the combination arm. Thus, we have planned this phase II study to evaluate the safety and preliminary efficacy of osimertinib plus cisplatin/carboplatin plus pemetrexed therapy for patients with previously untreated EGFR-mutated NSCLC.

      Patients and Methods

      A total of 66 patients will be enrolled, because this sample size will be adequate for assessing treatment safety and efficacy. The co-primary endpoints include safety and the objective response rate, and the secondary endpoints include the complete response rate, disease control rate, and progression-free survival.

      Conclusions

      This is the first study to explore the efficacy and safety of osimertinib combined with platinum-based chemotherapy in previously untreated NSCLC patients with EGFR-sensitizing mutations. Our findings could provide valuable information for phase III studies such as FLAURA2 and for developing treatment strategies for EGFR-mutated NSCLC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zhang Y.L.
        • Yuan J.Q.
        • Wang K.F.
        • et al.
        The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
        Oncotarget. 2016; 7: 78985-78993
        • Maemondo M.
        • Inoue A.
        • Kobayashi K.
        • et al.
        Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
        N Engl J Med. 2010; 362: 2380-2388
        • Mitsudomi T.
        • Morita S.
        • Yatabe Y.
        • et al.
        Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
        Lancet Oncol. 2010; 11: 121-128
        • Zhou C.
        • Wu Y.L.
        • Chen G.
        • et al.
        Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
        Lancet Oncol. 2011; 12: 735-742
        • Rosell R.
        • Carcereny E.
        • Gervais R.
        • et al.
        Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
        Lancet Oncol. 2012; 13: 239-246
        • Sequist L.V.
        • Yang J.C.
        • Yamamoto N.
        • et al.
        Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
        J Clin Oncol. 2013; 31: 3327-3334
        • Wu Y.L.
        • Zhou C.
        • Hu C.P.
        • et al.
        Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
        Lancet Oncol. 2014; 15: 213-222
        • Cross D.A.
        • Ashton S.E.
        • Ghiorghiu S.
        • et al.
        AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
        Cancer Discov. 2014; 4: 1046-1061
        • Ramalingam S.S.
        • Yang J.C.
        • Lee C.K.
        • et al.
        Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer.
        J Clin Oncol. 2018; 36: 841-849
        • Soria J.C.
        • Ohe Y.
        • Vansteenkiste J.
        • et al.
        Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.
        N Engl J Med. 2018; 378: 113-125
        • Ramalingam S.S.
        • Vansteenkiste J.
        • Planchard D.
        • et al.
        Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.
        N Engl J Med. 2020; 382: 41-50
        • Gandhi L.
        • Rodríguez-Abreu D.
        • Gadgeel S.
        • et al.
        Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.
        N Engl J Med. 2018; 378: 2078-2092
        • Soria J.C.
        • Wu Y.L.
        • Nakagawa K.
        • et al.
        Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
        Lancet Oncol. 2015; 16: 990-998
        • Hosomi Y.
        • Morita S.
        • Sugawara S.
        • et al.
        Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study.
        J Clin Oncol. 2020; 38: 115-123
        • Okada M.
        • Tanaka K.
        • Asahina H.
        • et al.
        Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.
        J Clin Oncol. 2018; 36: e21073
        • Takeda M.
        • Okamoto I.
        • Nakagawa K.
        Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
        J Thorac Oncol. 2014; 9: 200-204